Floatz logo

nkt5097 cdk2/cdk4 dual degrader

Hormone Receptor-Positive Breast Cancer

NiKang Therapeutics, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

116 Active assets in the Hormone Receptor-Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
EXEMESTANE
Fujian Cancer Hospital
Phase 4BBB
Everolimus
Ellipses Pharma
Phase 4BBB
Arimidex
University of Illinois at Chicago
Phase 4BBB
Ribociclib
BeOne Medicines
Phase 4BBB
Palbociclib
BeOne Medicines
Phase 3BBB

View all 50 →

Same molecule, other indications

nkt5097 cdk2/cdk4 dual degrader is also rated in:

CCNE1 Amplified Advanced Solid TumorsDormant
CC
Indicative ·
43 / 100
View asset →
HR+ HER2- Breast CancerDormant
CC
Indicative ·
43 / 100
View asset →
triple-negative breast carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →